BDBM603949 N-[1-Ethyl-1-[[(1S)-1-(hydroxymethyl)-3-methyl-butyl]carbamoyl]propyl]-5-(3-fluoroazetidin-1-yl)-6-[[(1R,2R)-2-(hydroxymethyl)cyclopropyl]methoxy]pyridine-2-carboxamide or N-[1-ethyl-1-[[(1S)-1-(hydroxymethyl)-3-methyl-butyl]carbamoyl]propyl]-5-(3-fluoroazetidin-1-yl)-6-[[(1S,2S)-2-(hydroxymethyl)cyclopropyl]methoxy]pyridine-2-carboxamide::US11655243, Example 27

SMILES CCC(CC)(NC(=O)c1ccc(N2CC(F)C2)c(OC[C@@H]2C[C@H]2CO)n1)C(=O)N[C@H](CO)CC(C)C

InChI Key InChIKey=FPMJZKMFSIVTAK-UHFFFAOYSA-N

Data  1 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 603949   

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603949(US11655243, Example 27 | N-[1-Ethyl-1-[[(1S)-1-(hy...)
Affinity DataKi:  4.15E+3nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent